Table 1 Epidemiological, clinical, therapeutic features and outcomes of reported cases of primary cardiac leiomyosarcomas
From: Two years survival of primary cardiac leiomyosarcoma managed by surgical and adjuvant therapy
Author | Age | Sex | Symptom | Site | Size (cm) | Surgery | Chemotherapy | Radiotherapy | Survival (months) | |
|---|---|---|---|---|---|---|---|---|---|---|
1 | Kornberg [8] | 21 | F | N | RA | 6 | R2 | Doxorubicin–ifosfamamide | N | 3 |
2 | Takamizawa [9] | 53 | M | Cough Inferior limbs oedema | RA | 3 | N | N | N | 0.5 |
3 | Fox [10] | 61 | M | Chest pain Vomiting | LV | 9 | R2 | N | N | 6 |
4 | Ishitoya [11] | 26 | F | Dyspnea Inferior limbs oedema | LA | 7 | R0 | N | N | 5 |
5 | Hattori [11] | 19 | M | Dyspnea Hemoptysis | LA | 13 | R0 | N | Y | 2 |
6 | Minakata [12] | 69 | F | Dyspnea Cyanosis | LA | 6 | R0 | N | N | 3 |
7 | Pins [13] | 29 | F | Chest pain | RV | 3 | R0 | N | N | NA |
8 | Pins [13] | 25 | M | Syncope | RA | 9 | R0 | Doxorubicin–Ifosfamide—Actino-Doxorubicin | Y | 60 |
9 | Minardi [14] | 67 | M | Dyspnea Cough | LA | 8 and 2 | R0 | N | N | 7 |
10 | Burnett [15] | 60 | F | Dyspnea | RV | NA | R2 | N | N | 0 |
11 | Andersen [16] | 86 | F | Pulmonary oedema | LA | 4 | R0 | N | N | 15 |
12 | Ogimoto [17] | 73 | F | Dyspnea | LA | NA | R0 | N | N | 3 |
13 | Willaret [18] | 70 | F | Dyspnea Chest pain Palpitation | RV | 4 | R0 | N | N | 7 |
14 | Strina [19] | 33 | F | Dyspnea Syncope | LA | 8 | R0 | Doxorubicin–Ifosfamide | Y | 29 |
15 | Lee [20] | 45 | F | Dyspnea | RV | 8 | R2 | Doxorubicin–Ifosfamide | N | NA |
16 | Malyshev [21] | 43 | F | Pulmonary oedema | LA | NA | R2 | Doxorubicin–Ifosfamide | N | 15 |
17 | Smith [22] | 40 | F | Dyspnea | LA | 7 | R1 | N | Y | 18 |
18 | Antunes [23] | 53 | F | Pulmonary oedema | LA | NA | R2 | Metoxantrone Dacarbazine Cyclophosphamide | N | 6 |
19 | Rastan [24] | 76 | F | Dyspnea | RV | 6 | R1 | N | N | NA |
20 | Antunes [23] | 33 | F | Anorexia Tirednes, Dyspnea Chest tightness | RA | 4 | R0 | N | N | 5 |
21 | Astarcıoğlu [25] | 40 | F | Dyspnea | RV | 9 | R0 | Doxorubicin | N | 42 |
22 | Glaoui [26] | 47 | M | Pulmonary oedema Dyspnea | RA | 5 | R0 | Doxorubicin–Ifosfamide | N | 7 |
23 | Nakanishi [27] | 74 | M | Dyspnea | LA | NA | R0 | N | Y | 8 |
24 | Wilbring [28] | 43 | M | Paravertebral back pain Dyspnea | LA | 6 | R0 | N | Y | 9 |
25 | Parissis [29] | 36 | M | Dyspnea | RA | NA | R0 | Doxorubicin–Ifosfamide | N | NA |
26 | Mazzolla [30] | 21 | F | N | LA | 7 | R0 | Doxorubicin–Ifosfamide- cisplatin | N | 24 |
27 | Esaki [31] | 68 | M | Dyspnea | RV | NA | R0 | N | N | 2 |
28 | Guschmann [32] | 61 | F | Dyspnea | LA | NA | R0 | Y | N | NA |
29 | Davis [33] | 65 | F | Dyspnea Chest pain | LA | 6 | R0 | Y | N | 18 |
30 | Panday [34] | 67 | M | Dyspnea | RV | NA | R0 | N | N | 36 |
31 | Pessotto [35] | 24 | M | Syncope Atrial fibrillation | LA | 7 | R1 | Doxorubicin–Ifosfamide—Actino-Doxorubicin | Y | 84 |
32 | Lo [36] | 28 | F | Long term fever Body weight loss | LA | 5 | R0 | Y | N | 5 |